Adjuvant Therapy News and Research

RSS

Adjuvant Therapy is treatment given after the primary treatment to increase the chances of a cure. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, or biological therapy.

Genes can be used to better predict the likelihood of kidney cancer recurrence

A decade-long international study into kidney cancer has shown that doctors can predict the likelihood of a patient's disease returning by looking at DNA mutations in their tumors.

24 Feb 2023

Olfactory receptor gene may drive breast cancer metastasis to the brain

An olfactory receptor gene that aids in the sense of smell may also play a role in the metastasis of breast cancer to the brain, bones and lung, researchers from Massachusetts General Hospital have found.

4 Jan 2022

Immunotherapy following kidney cancer surgery prolonged disease-free survival rates

Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy in this patient population.

4 Jun 2021

Study reveals mechanism by which ibuprofen prevents RAC1B alternative splicing in colorectal cells

Oncotarget published "Ibuprofen disrupts a WNK1/GSK3β/SRPK1 protein complex required for expression of tumor-related splicing variant RAC1B in colorectal cells" which reported that although the molecular mechanism behind the antitumor properties of NSAIDs has been largely attributed to inhibition of cyclooxygenases , several studies have shown that the chemopreventive properties of ibuprofen also involve multiple COX-independent effects.

23 Mar 2021

Genetic test identifies patients with invasive lobular carcinoma at high risk of recurrence

New results to be presented at the 12th European Breast Cancer Conference show that a test, which looks at the activity of 70 genes in breast cancer tissue, is possible to use in the clinic to identify patients with invasive lobular carcinoma (ILC) that is at high risk of recurring and progressing.

1 Oct 2020